SELLAS Life Sciences Group, Inc. Contingent Consideration Classified as Equity, Fair Value Disclosure
SELLAS Life Sciences Group, Inc. (SLS) had Contingent Consideration Classified as Equity, Fair Value Disclosure of $7.58 million as of 2013-03-31, per its 10-Q filed 2013-05-09.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure · last filed 2013-05-09
- 2013-03-31: Contingent Consideration Classified as Equity, Fair Value Disclosure $7.58M.
- 2012-12-31: Contingent Consideration Classified as Equity, Fair Value Disclosure $7.14M.
- 2012-09-30: Contingent Consideration Classified as Equity, Fair Value Disclosure $6.79M.
- 2012-06-30: Contingent Consideration Classified as Equity, Fair Value Disclosure $6.32M.
| Period end | Contingent Consideration Classified as Equity, Fair Value Disclosure |
|---|---|
| 2013-03-31 | $7.58M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $7.14M 10-Q · filed 2013-05-09 |
| 2012-09-30 | $6.79M 10-Q · filed 2012-11-13 |
| 2012-06-30 | $6.32M 10-Q · filed 2012-11-13 |
| 2011-12-31 | $6.35M 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |